Biotechnology

Filter

Current filters:

None

Popular Filters

1 to 25 of 2320 results

Australian government announces funding available for Soliris

18-09-2014

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended to the Australian government that…

Alexion PharmaceuticalsAustraliaBiotechnologyFinancialPricingRare diseasesSoliris

EuropaBio calls for EMA action on labeling of biosimilars

18-09-2014

EuropaBio has published a statement giving the perspective of the health care biotechnology industry…

BiosimilarsBiotechnologyEuropeRegulation

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

17-09-2014

US biotech major Gilead Sciences has announced disappointing results from a Phase II study evaluating…

BiotechnologyGilead SciencesOncologyResearchsimtuzumabUSA

Celgene cancer drug approved for PBS listing in Australia

17-09-2014

Pancreatic cancer drug Abraxane (paclitaxel protein-bound particles for injectable suspension), from…

AbraxaneAustraliaBiotechnologyCelgene Corp.FinancialOncologyPricing

Dimension Therapeutics appoints Annalisa Jenkins as chief executive

Dimension Therapeutics appoints Annalisa Jenkins as chief executive

17-09-2014

Dimension Therapeutics, a US gene therapy company focused on rare diseases, has appointed Annalisa Jenkins…

BiotechnologyBoardroomDimension TheapeuticsDimension TherapeuticsUSA

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

17-09-2014

Privately-held San Diego, USA-based biotech firm Denovo Biopharma has acquired enzastaurin, a late-stage…

BiotechnologyDenovo BiopharmaEli LillyenzastaurinGlobalLicensingOncology

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

17-09-2014

The UK’s Department of Health announced that DCVax-L, the dendritic cell-based vaccine from US company…

BiotechnologyDCVaxNorthwest BiotherapeuticsOncologyRegulationUK

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

16-09-2014

US biotech firm Regeneron Pharmaceuticals says that the US Food and Drug Administration has granted Eylea…

BayerBiotechnologyEyleaOphthalmicsRegeneron PharmaceuticalsRegulationUSA

SIGA Technologies files for Chapter 11 reorganization

SIGA Technologies files for Chapter 11 reorganization

16-09-2014

Biological warfare defense firm SIGA Technologies has filed a voluntary petition for relief under chapter…

Anti-viralsBiotechnologyFinancialLegalPharmAtheneSIGA TechnologiesTecovirimatUSA

Amgen updates on Prolia in postmenopausal osteoporosis

Amgen updates on Prolia in postmenopausal osteoporosis

16-09-2014

USA-based Amgen has released results from a new exploratory analysis of the open-label extension study…

AmgenAnti-Arthritics/RheumaticsBiotechnologyProliaResearchWomen's Health

India’s Dept of Biotech plans financial help for the biotech industry

India’s Dept of Biotech plans financial help for the biotech industry

15-09-2014

Anti-cancer compounds, immunogens against H1N1, cheap recombinant human insulin, stem cell research -…

BiotechnologyFinancialIndiaResearch

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Merck Serono pulls plug on tecemotide in Stage III NSCLC

Merck Serono pulls plug on tecemotide in Stage III NSCLC

12-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, is to discontinue the clinical development…

BiotechnologyGermanyMerck SeronoOncologyResearch

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

Biogen Idec's Plegridy achieves positive results over two years in multiple sclerosis

12-09-2014

US biotech firm Biogen Idec has reported data confirming its Plegridy gives provides treatment effects…

Biogen IdecBiotechnologyNeurologicalPlegridyResearchUSA

Strong and sustained efficacy reported for Tecfidera over five years

Strong and sustained efficacy reported for Tecfidera over five years

12-09-2014

Results from a five-year study with US biotech firm Biogen Idec’s Tecfidera show strong and sustained…

Biogen IdecBiotechnologyNeurologicalResearchTecfideraUSA

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

11-09-2014

Clinical stage oncology drug development company MabVax Therapeutics has entered agreements with Memorial…

BiotechnologyCancer therapeuticsChimeric antigen receptorMabVax TherapeuticsOncologyResearchUSA

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

10-09-2014

Biotech companies Seattle Genetics of the USA and Denmark’s Genmab have entered into an additional…

BiotechnologyGenmabHuMax-TACLicensingOncologyResearchSeattle Genetics

1 to 25 of 2320 results

Back to top